Business Performance

Business Performance

We have a track record of contract work across various phases and a wide range of disease areas,
earning the trust of many clients in the development process of numerous compounds.

  • Business Experienceover48years
  • Number of Conducted Studiesover80,000
  • Number of Clientsover1,800

Central Laboratory Services (CLS)※Proportion of Studies: 2022 - 2024

By Therapeutic Area
By Development Phase

Bioanalytical Services (BAS)※Proportion of Studies: 2022 - 2024

By Methodology (Equipment)
Item Main Method (Equipment)
PK・ADA・Nab LC/MS, ELISA, ECL, Gyrolab, CBA(Cell-based Assay), etc.
Biomarker 1 LC/MS, ELISA, Digital ELISA, ECL, Bio-Plex, FCM(Flow Cytometry), CyTOF, ELISPOT, etc.
Biomarker 2 Genetic analysis: PCR, Array, Sequencer, nCounter, IHC, etc.
Biobanking Stored samples: Blood, Serum, Plasma, Tissue Slide, DNA, etc.
Others PBMC isolation, DNA extraction, RNA extraction, etc.

Nonclinical Contract Research※Proportion of Studies: 2022 - 2024

Pharmacology Studies By Disease Area
Safety Studies By Product Category